药理上的CDK4/6抑制促进乳腺癌中对 lysosomotropic 药物的脆弱性
Jamil Nehme1, Sjors Maassen1, Sara Bravaccini2
1European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), University of Groningen (RUG), Groningen, The Netherlands.
这项针对耐药乳腺癌的研究表明,循环素依赖性激酶4/6抑制剂 (CDK4/6i) 会增加 lysosomal 质量. 这使得癌细胞易受 lysosomotropic 药物影响,提供了一种新的序列治疗方法.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药物发现 药物发现 药物发现
背景情况:
- 乳腺癌是一个主要的全球健康问题,循环素依赖性激酶4和6抑制剂 (CDK4/6i) 用于通过诱导衰老来减缓瘤生长.
- 耐药性限制了CDK4/6i的长期有效性,需要采取消除衰老癌细胞的策略.
研究的目的:
- 研究CDK4/6i治疗的乳腺癌细胞中的新疗法漏洞.
- 确定能够清除CDK4/6i诱导的衰老类细胞的药物,以提高治疗的耐用性.
主要方法:
- 在接受CDK4/6i治疗的乳腺癌细胞中分析与衰老相关的表型.
- 在暴露于CDK4/6i后评估溶酶体质量和结构变化.
- 在临床前模型中测试 lysosomotropic 剂 (LLOMe,salinomycin) 与 CDK4/6i 结合的疗效.
主要成果:
- 经过CDK4/6i治疗的乳腺癌细胞虽然类似于老化,但对传统的老化药物有抗性.
- CDK4/6i治疗显著增加了乳腺癌细胞的溶酶体质量,并改变了乳腺癌细胞的溶酶体结构.
- 用CDK4/6i和 lysosomotropic药物的连续治疗有效地抑制了瘤生长,无论是HR+还是某些TNBC模型,都在体内.
结论:
- CDK4/6i诱导乳腺癌细胞中的溶酶体脆弱性,使它们对溶酶体转移剂敏感.
- 结合CDK4/6i和 lysosomotropic 剂的顺序治疗策略显示出克服药物耐药性和减少复发的希望.
- 这种方法可以通过向衰老类细胞来提高乳腺癌治疗的整体疗效.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Drugs that Destabilize Microtubules
Mitogens and the Cell Cycle
